Primary prophylaxis of variceal bleeding in cirrhosis

A cost- effectiveness analysis

J. C. Teran, Thomas Imperiale, K. D. Mullen, A. S. Tavill, A. J. McCullough

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Background and Aims: Prophylaxis against the first variceal bleeding has been proposed to reduce morbidity and mortality in cirrhotic patients. No previous information is available regarding the cost-effectiveness of prophylaxis. The aim of this study was to compare the cost-effectiveness of variceal bleeding prophylaxis with propranolol, sclerotherapy, and shunt surgery in cirrhotic patients stratified by bleeding risk. Methods: A hypothetical cohort was stratified according to bleeding risk. The natural history of cirrhosis with esophageal varices was simulated using a Markov model. Transitional probabilities extracted from published studies and costs were obtained from our institution's billing department. Sensitivity analyses were performed for important variables. Results: Propranolol results in cost savings ranging between $450 and $14,600 over a 5-year period. The extent of cost savings depended on the individual patient's bleeding risk. In addition, propranolol increased the quality-adjusted life expectancy by 0.1-0.4 years. Sclerotherapy was significantly less cost-effective than propranolol and had no advantage on quality of life. Shunt surgery was effective therapy for prevention of bleeding but decreased life expectancy and quality of life in some risk groups and was not cost-effective. Conclusions: Propranolol is the only cost-effective form of prophylactic therapy for preventing initial variceal bleeding in cirrhosis regardless of bleeding risk.

Original languageEnglish (US)
Pages (from-to)473-482
Number of pages10
JournalGastroenterology
Volume112
Issue number2
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Cost-Benefit Analysis
Fibrosis
Hemorrhage
Propranolol
Quality of Life
Costs and Cost Analysis
Sclerotherapy
Cost Savings
Life Expectancy
Esophageal and Gastric Varices
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Primary prophylaxis of variceal bleeding in cirrhosis : A cost- effectiveness analysis. / Teran, J. C.; Imperiale, Thomas; Mullen, K. D.; Tavill, A. S.; McCullough, A. J.

In: Gastroenterology, Vol. 112, No. 2, 1997, p. 473-482.

Research output: Contribution to journalArticle

Teran, J. C. ; Imperiale, Thomas ; Mullen, K. D. ; Tavill, A. S. ; McCullough, A. J. / Primary prophylaxis of variceal bleeding in cirrhosis : A cost- effectiveness analysis. In: Gastroenterology. 1997 ; Vol. 112, No. 2. pp. 473-482.
@article{5e3779b6ca1543b5ade8557bffa409ad,
title = "Primary prophylaxis of variceal bleeding in cirrhosis: A cost- effectiveness analysis",
abstract = "Background and Aims: Prophylaxis against the first variceal bleeding has been proposed to reduce morbidity and mortality in cirrhotic patients. No previous information is available regarding the cost-effectiveness of prophylaxis. The aim of this study was to compare the cost-effectiveness of variceal bleeding prophylaxis with propranolol, sclerotherapy, and shunt surgery in cirrhotic patients stratified by bleeding risk. Methods: A hypothetical cohort was stratified according to bleeding risk. The natural history of cirrhosis with esophageal varices was simulated using a Markov model. Transitional probabilities extracted from published studies and costs were obtained from our institution's billing department. Sensitivity analyses were performed for important variables. Results: Propranolol results in cost savings ranging between $450 and $14,600 over a 5-year period. The extent of cost savings depended on the individual patient's bleeding risk. In addition, propranolol increased the quality-adjusted life expectancy by 0.1-0.4 years. Sclerotherapy was significantly less cost-effective than propranolol and had no advantage on quality of life. Shunt surgery was effective therapy for prevention of bleeding but decreased life expectancy and quality of life in some risk groups and was not cost-effective. Conclusions: Propranolol is the only cost-effective form of prophylactic therapy for preventing initial variceal bleeding in cirrhosis regardless of bleeding risk.",
author = "Teran, {J. C.} and Thomas Imperiale and Mullen, {K. D.} and Tavill, {A. S.} and McCullough, {A. J.}",
year = "1997",
doi = "10.1053/gast.1997.v112.pm9024301",
language = "English (US)",
volume = "112",
pages = "473--482",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Primary prophylaxis of variceal bleeding in cirrhosis

T2 - A cost- effectiveness analysis

AU - Teran, J. C.

AU - Imperiale, Thomas

AU - Mullen, K. D.

AU - Tavill, A. S.

AU - McCullough, A. J.

PY - 1997

Y1 - 1997

N2 - Background and Aims: Prophylaxis against the first variceal bleeding has been proposed to reduce morbidity and mortality in cirrhotic patients. No previous information is available regarding the cost-effectiveness of prophylaxis. The aim of this study was to compare the cost-effectiveness of variceal bleeding prophylaxis with propranolol, sclerotherapy, and shunt surgery in cirrhotic patients stratified by bleeding risk. Methods: A hypothetical cohort was stratified according to bleeding risk. The natural history of cirrhosis with esophageal varices was simulated using a Markov model. Transitional probabilities extracted from published studies and costs were obtained from our institution's billing department. Sensitivity analyses were performed for important variables. Results: Propranolol results in cost savings ranging between $450 and $14,600 over a 5-year period. The extent of cost savings depended on the individual patient's bleeding risk. In addition, propranolol increased the quality-adjusted life expectancy by 0.1-0.4 years. Sclerotherapy was significantly less cost-effective than propranolol and had no advantage on quality of life. Shunt surgery was effective therapy for prevention of bleeding but decreased life expectancy and quality of life in some risk groups and was not cost-effective. Conclusions: Propranolol is the only cost-effective form of prophylactic therapy for preventing initial variceal bleeding in cirrhosis regardless of bleeding risk.

AB - Background and Aims: Prophylaxis against the first variceal bleeding has been proposed to reduce morbidity and mortality in cirrhotic patients. No previous information is available regarding the cost-effectiveness of prophylaxis. The aim of this study was to compare the cost-effectiveness of variceal bleeding prophylaxis with propranolol, sclerotherapy, and shunt surgery in cirrhotic patients stratified by bleeding risk. Methods: A hypothetical cohort was stratified according to bleeding risk. The natural history of cirrhosis with esophageal varices was simulated using a Markov model. Transitional probabilities extracted from published studies and costs were obtained from our institution's billing department. Sensitivity analyses were performed for important variables. Results: Propranolol results in cost savings ranging between $450 and $14,600 over a 5-year period. The extent of cost savings depended on the individual patient's bleeding risk. In addition, propranolol increased the quality-adjusted life expectancy by 0.1-0.4 years. Sclerotherapy was significantly less cost-effective than propranolol and had no advantage on quality of life. Shunt surgery was effective therapy for prevention of bleeding but decreased life expectancy and quality of life in some risk groups and was not cost-effective. Conclusions: Propranolol is the only cost-effective form of prophylactic therapy for preventing initial variceal bleeding in cirrhosis regardless of bleeding risk.

UR - http://www.scopus.com/inward/record.url?scp=0031047355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031047355&partnerID=8YFLogxK

U2 - 10.1053/gast.1997.v112.pm9024301

DO - 10.1053/gast.1997.v112.pm9024301

M3 - Article

VL - 112

SP - 473

EP - 482

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -